Healthcare
Live Price
Offline$0.67
-2.90% today
1Y Change
-70.41%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VistaGen Therapeutics, Inc. (VTGN) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $0.67 and down 70.4% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -54.3%, EPS growth of -9.9%, a dividend yield of 0.0%. What stands out right now is revenue -54.3%, EPS -9.9%, free cash flow -63.4% with operating margin -8847.8% and ROIC -133.1%. Valuation already assumes a fairly strong business story at price/sales 25.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VTGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VTGN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VTGN Max Drawdown
-89.59%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VTGN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1M
-1.7% YoY
FY Net Income
-$17.9M
+62.5% YoY
Free Cash Flow
-$12.3M
+72.8% YoY
Revenue Growth
-54.3%
EPS Growth
-9.9%
Gross Margin
54.7%
Net Margin
-8486.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 486K | 1M | -227K | 1M | 1M |
| Gross Profit | 486K | 1M | -227K | 1M | 1M |
| Operating Income | -56M | -33M | -59M | -48M | -18M |
| EBITDA | -55M | -32M | -59M | -47M | -17M |
| Net Income | -51M | -29M | -59M | -48M | -18M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 67M | 119M | 17M | 68M | 103M |
| Total Assets | 84M | 124M | 21M | 75M | 108M |
| Total Liabilities | 14M | 9M | 9M | 10M | 16M |
| Shareholder Equity | 70M | 114M | 12M | 65M | 92M |
| Total Debt | 2M | 2M | 3M | 3M | 4M |
| Net Debt | -66M | -117M | -14M | -65M | -99M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+73.3% YoY
Capital Expenditures
275K
-37.4% YoY
Free Cash Flow
12M
+72.8% YoY
Key ratios
Gross Margin
54.7%
Operating Margin
-8847.8%
Net Margin
-8486.8%
ROE
-109.7%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.